Brief: Morphosys To Present New Phase 3 Manifest-2 Data On Pelabresib In Myelofibrosis
April 24 (Reuters) - MORPHOSYS AG MORG.DE :
* MORPHOSYS TO PRESENT NEW PHASE 3 MANIFEST-2 DATA ON
PELABRESIB
IN MYELOFIBROSIS IN ORAL PRESENTATION AT 2024 ASCO ANNUAL
MEETING
Source text for Eikon: ID:nEQ81FfT1a
Further company coverage: MORG.DE
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Morphosys AG
See all newsBrief: Morphosys Announces Voluntary Delisting From The Nasdaq Global Market
Brief: Morphosys Says Merger Squeeze-Out Cash Compensation Determined At Eur 68.00
Brief: Morphosys And Novartis Sign Delisting Agreement
Brief: Novartis BidCo Germany plans merger squeeze-out of Morphosys minority shareholders
Brief: Morphosys: Pichota and Lukas Gilgen replacing CEO And CFO